|
2025 Journal Article Non-pharmacological supportive care interventions during immunotherapy for people with cancer: a systematic scoping review and future directionsFarley, Morgan J., Scanlon, Brighid, Crichton, Megan, Bigaran, Ashley, Barnes, Amy, Hart, Nicolas H., Yates, Patsy M., Eastgate, Melissa and Alexander, Kim (2025). Non-pharmacological supportive care interventions during immunotherapy for people with cancer: a systematic scoping review and future directions. Current Oncology Reports, 27 (12), 1507-1523. doi: 10.1007/s11912-025-01714-x |
|
2025 Conference Publication Australian patients with IDH<sub>1 </sub>mutatedcholangiocarcinoma treated with ivosidenib: initial resultsfrom the phase 3b ProvIDHe studyPrice, Tim, Sim, Hao-Wen, Eastgate, Melissa, Mclachlan, Sue-Anne, Dean, Andrew, George, David, Weeratunge, Roshi, Zhang, Yoz and Oo, Maung Maung (2025). Australian patients with IDH1 mutatedcholangiocarcinoma treated with ivosidenib: initial resultsfrom the phase 3b ProvIDHe study. HOBOKEN: WILEY. |
|
2025 Conference Publication Retrospective cohort study of Treatment Patterns and Outcomes for Patients with locally advanced Rectal Cancer across Three Metropolitan Hospitals in BrisbaneMacilwraith, Philip, Turner, Cassie, Roberts, Kate, Bigby, Kieron, Kang, Sebastian, Wyld, David, Burge, Matthew and Eastgate, Melissa (2025). Retrospective cohort study of Treatment Patterns and Outcomes for Patients with locally advanced Rectal Cancer across Three Metropolitan Hospitals in Brisbane. HOBOKEN: WILEY. |
|
2025 Conference Publication Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) plus bevacizumab (B) plus transarterial chemoembolization (TACE) and placebos plus TACE: EMERALD-1 post hoc analysisRoderburg, C., Sangro, B., Bouattour, M., Park, J. -W., Romero, M. Del Consuelo Diaz, Erinjeri, J. P., Alves, G., Gu, S., Manikhas, A., Kuroda, H., Suksombooncharoen, T., Vo, T. Hoi Trung, Ostwal, V. S., Eastgate, M., Vaccaro, G., Griffin, R., Ali, S., Balaji, K. and Chan, S. L. (2025). Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) plus bevacizumab (B) plus transarterial chemoembolization (TACE) and placebos plus TACE: EMERALD-1 post hoc analysis. BASEL: KARGER. |
|
2025 Conference Publication Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D)+bevacizumab (B)+transarterial chemoembolization (TACE) and placebos+TACE: EMERALD-1 post hoc analysisRoderburg, C., Sangro, B., Bouattour, M., Park, J-W., del Consuelo Díaz Romero, M., Erinjeri, J. P., Alves, G., Gu, S., Manikhas, A., Kuroda, H., Suksombooncharoen, T., Hoi Trung Vo, T., Ostwal, V. S., Eastgate, M., Vaccaro, G., Griffin, R., Ali, S., Balaji, K. and Chan, S. L. (2025). Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D)+bevacizumab (B)+transarterial chemoembolization (TACE) and placebos+TACE: EMERALD-1 post hoc analysis. Annual conference of the German Society of Gastroenterology, and Digestive and Metabolic Diseases with Endoscopy Section (DGVS) Viszeralmedizin 2025, Leipzig, Germany, 15–20 September 2025. Stuttgart, Germany: Georg Thieme. doi: 10.1055/s-0045-1810980 |
|
2025 Journal Article Depleting the action of EZH2 through PI3K-mTOR inhibition to overcome metastasis and immunotherapy resistance in triple-negative breast cancerMelino, Michelle, Tu, Wen Juan., Bielefeldt-Ohmann, Helle, Proctor, Martina, Ahuja, Taniya, Vandermeide, John, Bain, Amanda L., Nallan, Gahyathiri, Goh, Sal Lee, Prasanna, Thiru, Dahlstrom, Jane E., Miranda, Mariska, Choudhary, Ramesh Kumar., Anandam, Aravind, Chaudhary, Sumit, Seal, Jonathan T., Sinha, Debottam, Zhang, Shaoqian, Nguyen, Tam Hong., Srihari, Sriganesh, Hartel, Gunter, Ives, Amy, Malik, Laeeq, Yip, Desmond, Nottage, Michelle, Eastgate, Melissa and Rao, Sudha (2025). Depleting the action of EZH2 through PI3K-mTOR inhibition to overcome metastasis and immunotherapy resistance in triple-negative breast cancer. Molecular Cancer Therapeutics, 24 (10), 1511-1526. doi: 10.1158/1535-7163.mct-24-0693 |
|
2025 Conference Publication Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) + bevacizumab (B) + transarterial chemoembolization (TACE) and placebos + TACE: EMERALD-1 post hoc analysisSangro, Bruno, Bouattour, Mohamed, Park, Joong-Won, Diaz, Dr. Consuelo, Erinjeri, Joseph P., Alves, Gustavo Vasconcelos, Gu, Shan-Zhi, Manikhas, Aleksei, Kuroda, Hidekatsu, Suksombooncharoen, Thatthan, Vo, Truc Hoi Trung, Ostwal, Vikas S., Eastgate, Melissa A., Vaccaro, Gina M., Griffin, Rebecca, Ali, Sajid, Balaji, Kavitha and Chan, Stephen Lam (2025). Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) + bevacizumab (B) + transarterial chemoembolization (TACE) and placebos + TACE: EMERALD-1 post hoc analysis. 2025 ASCO Gastrointestinal (GI) Cancers Symposium, San Francisco, CA United States, 23 - 25 January 2025. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.4_suppl.574 |
|
2025 Journal Article Catheter-related thrombosis in adults with cancer: a secondary analysis of a prospective randomised controlled trialHapgood, Greg, Hill, Kate, Okano, Satomi, Abro, Emad, Looke, David, Kennedy, Glen, Pavilion, Gilbert, Van Kuilenburg, Rosita, Geary, Alanna, Joubert, Warren, Eastgate, Melissa, Jones, Mark and Mollee, Peter (2025). Catheter-related thrombosis in adults with cancer: a secondary analysis of a prospective randomised controlled trial. Journal of Thrombosis and Haemostasis, 23 (2), 627-634. doi: 10.1016/j.jtha.2024.11.002 |
|
2025 Journal Article Cost-effectiveness analysis of microwave ablation versus robot-assisted partial nephrectomy for patients with small renal masses in AustraliaXia, Qing, Senanayake, Sameera Jayan, Kularatna, Sanjeewa, Brain, David, McPhail, Steven M., Parsonage, Will, Eastgate, Melissa, Barnes, Annette, Brown, Nick and Carter, Hannah E. (2025). Cost-effectiveness analysis of microwave ablation versus robot-assisted partial nephrectomy for patients with small renal masses in Australia. Urologic Oncology, 43 (1), 62.e15-62.e26. doi: 10.1016/j.urolonc.2024.09.016 |
|
2024 Conference Publication Baseline characteristics and molecular testing of Australian patients with IDH1 mutated cholangiocarcinoma: initial results from the phase IIIb ProvIDHe studySim, H-W., McLachlan, S-A., Dean, A., Price, T.J., Eastgate, M., Rimassa, L., Mercade, T. Macarulla, Malka, D., Gharbi, H., Robert, R., Sullivan, A. and Vogel, A. (2024). Baseline characteristics and molecular testing of Australian patients with IDH1 mutated cholangiocarcinoma: initial results from the phase IIIb ProvIDHe study. ESMO Asia Congress 2024, Singapore, 6 – 8 December 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2024.10.171 |
|
2024 Journal Article Patient Reported Outcome Measures in cancer care: a hybrid effectiveness-Implementation trial to optimise Symptom control and health service Experience (PROMISE)–protocol for a randomised controlled trial of electronic self-reporting of symptoms versus usual care during and following treatment in patients with cancerWebb, Penelope M, Brown, Amy, Brown, Bena, Collins, Louisa G, Crawford Williams, Fiona, Doupain, Kerrie, Eastgate, Melissa, Fennelly, Vicki, Girgis, Afaf, Hartel, Gunter, Ladwa, Rahul, Martin, Karen, Mason, Robert, McGuire, Peter, Miller, Elizabeth, O’Brien, Suzanne, Packer, Rebecca, Pinkham, Mark B, Sabesan, Sabe, Sanmugarajah, Jasotha, Slapp, Georgia, Tapsall, Doreen, White, Jeanie, Wishart, Laurelie R, Wyld, David and Chan, Raymond J (2024). Patient Reported Outcome Measures in cancer care: a hybrid effectiveness-Implementation trial to optimise Symptom control and health service Experience (PROMISE)–protocol for a randomised controlled trial of electronic self-reporting of symptoms versus usual care during and following treatment in patients with cancer. BMJ Open, 14 (11) e090836, 1-10. doi: 10.1136/bmjopen-2024-090836 |
|
2024 Conference Publication "Signing up for the PRoCESS [Pancreatic cancer Relatives Counselling and Education Support Service] Trial was the most important thing I did as a carer"Beesley, Vanessa L., Roset, Natalie, Turner, Jane, Yates, Patsy, Wyld, David, Eastgate, Melissa, Chan, Raymond, Collins, Louisa, Stewart, Michelle, Beebe, Hanna, Malt, Maryrose, Kelly, Caroline and Neale, Rachel (2024). "Signing up for the PRoCESS [Pancreatic cancer Relatives Counselling and Education Support Service] Trial was the most important thing I did as a carer". COSA's 51st Annual Scientific Meeting: Bridging gaps, building progress, breaking down disparities, Gold Coast, QLD, Australia, 13 - 15 November 2024. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.14116 |
|
2024 Journal Article Bolusing IV administration sets with monoclonal antibodies reduces cost and chair time: a randomized controlled trialBoyte, M. Francesca, Scanlon, Gradcert Brighid, Matthews, Robyn, Button, Elise, Jones, Lee, Hayes, Therese, Partridge, Grant, Smith, Michael, Kennedy, Glen Andrew, Eastgate, Melissa and Gavin, Nicole Clare (2024). Bolusing IV administration sets with monoclonal antibodies reduces cost and chair time: a randomized controlled trial. Clinical Journal of Oncology Nursing, 28 (5), E9-E15. doi: 10.1188/24.CJON.E9-E15 |
|
2024 Conference Publication Routine, prospective DPYD genotyping guided dose-individualisation for patients receiving fluoropyrimidines: Implementation, prevalence and patient safety outcomes from a multi-institutional clinical trialNalder, Mark, Kulasegaran, Tivya, Lundie, Ben, Woods, Rick, Eastgate, Melissa A., Wyld, David and Burge, Matthew E. (2024). Routine, prospective DPYD genotyping guided dose-individualisation for patients receiving fluoropyrimidines: Implementation, prevalence and patient safety outcomes from a multi-institutional clinical trial. 2024 ASCO Annual Meeting, Chicago, IL, United States, 31 May–4 June 2024. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2024.42.16_suppl.12121 |
|
2024 Journal Article Exploring the administration of intravenous antibiotics and fluids via portable intravenous pump versus intravenous pump and pole to improve mobility in patients diagnosed with cancer (The ACTIVE Trial): A randomized controlled trial protocolMatthews, Robyn, Russell, Emily, Wessling, Claire, Sandler, Carolina, Eastgate, Melissa, Hajkowicz, Krispin, Pavey, Toby, Clark, Bronwyn K., Scanlon, Brighid and Gavan, Nicole C. (2024). Exploring the administration of intravenous antibiotics and fluids via portable intravenous pump versus intravenous pump and pole to improve mobility in patients diagnosed with cancer (The ACTIVE Trial): A randomized controlled trial protocol. Vascular Access Journal of the Canadian Vascular Access Association, 18 (2), 44-58. doi: 10.5737/va.v18.i2.44 |
|
2023 Journal Article Does bolusing intravenous administration sets with monoclonal antibodies reduce chair time in the oncology outpatient setting? A protocol for a randomized controlled trialGavin, Nicole, Boyte, Francesca, Matthews, Robyn, Button, Elise, Jones, Lee, Hayes, Therese, Partridge, Grant, Smith, Michael, Kennedy, Glen and Eastgate, Melissa (2023). Does bolusing intravenous administration sets with monoclonal antibodies reduce chair time in the oncology outpatient setting? A protocol for a randomized controlled trial. Vascular Access, 17 (3), 8-25. |
|
2023 Conference Publication Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic esophageal and gastroesophageal carcinoma with dysphagia: A single arm phase 2 clinical trial, PALEODay, Fiona, Sridharan, Swetha, Michael, Michael, Christophersen, Louise, Moore, Melissa M., Eastgate, Melissa A., Thompson, Stephen, MWEEMPWA, ANGELA, Oldmeadow, Christopher, Fraser, Allison and Martin, Jarad (2023). Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic esophageal and gastroesophageal carcinoma with dysphagia: A single arm phase 2 clinical trial, PALEO. 2023 ASCO Annual Meeting, Chicago, IL United States, 2-6 June 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.16_suppl.tps4172 |
|
2023 Journal Article Investigating the dietary knowledge, attitudes, and beliefs of Australian patients with cancerLee, Shu Fen, Brown, Teresa, Wyld, David, Edwards, Anna and Eastgate, Melissa (2023). Investigating the dietary knowledge, attitudes, and beliefs of Australian patients with cancer. Journal of Human Nutrition and Dietetics, 36 (3), 612-621. doi: 10.1111/jhn.13091 |
|
2023 Conference Publication CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanomaLau, Peter Kar Han, Harris, Samuel John, Eastgate, Melissa A., Kee, Damien, Mant, Andrew, Nott, Louise M., Gedye, Craig, Inderjeeth, Andrisha Jade, Underhill, Craig, Weppler, Alison Margaret, Wallace, Roslyn, Lee, Belinda, Au-Yeung, George, Williams, Narelle, Ariza Ospino, Daniel, Gonzales, Louise, Shackleton, Mark J., Lo, Serigne N., McArthur, Grant A. and Sandhu, Shahneen (2023). CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma. 2023 ASCO Annual Meeting, Chicago, IL United States, 2-6 June 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.16_suppl.9525 |
|
2022 Conference Publication A multicenter, randomized, double-blind phase III study of HBI-8000 combined with nivolumab versus placebo with nivolumab in patients with unresectable or metastatic melanoma not previously treated with PD-1 or PD-L1 inhibitorsKhushalani, N.I., Shue, H., Gedye, C., Mazumder, A., Sharma, S., Eastgate, M., Majem Tarruella, M., Antonanzas Basa, M., Montaudie, H., Marais-Nieman, R., de la Cruz Merino, L., Clements, A., Mortier, L., Jameson, M., Shojaei, F., Ning, J., Aiyer, L., Gillings, M., Kabbinavar, F. and Ascierto, P. (2022). A multicenter, randomized, double-blind phase III study of HBI-8000 combined with nivolumab versus placebo with nivolumab in patients with unresectable or metastatic melanoma not previously treated with PD-1 or PD-L1 inhibitors. ESMO Asia Congress 2022, Singapore, 2-4 December 2022. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2022.10.052 |
